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Introduction
Hypoparathyroidism is a heterogeneous clinical condition
(Table I) (1). It manifests when parathyroid hormone (PTH)
produced by parathyroid glands is unable to maintain normal
extracellular fluid concentrations of calcium ions, for insufficient
secretion or inadequate action on target tissues despite normal
or high circulating levels of the hormone (pseudo-hypoparathy -
r o i d i s m) (1, 2). 1,25-dihydroxyvitamin D [1,25(OH)2D] produc-
tion is also decreased, leading to a bi-hormonal deficiency (1).
The predominant clinical manifestations of hypoparathyroidism
are related to hypocalcemia. In the acute setting, neuromuscu-
lar irritability, including perioral paresthesias, tingling of the fin-
gers and toes and spontaneous or latent tetany with general-
ized tonic-clonic seizures and laryngeal spasm can be evident.
Chronically, hypocalcemia can be asymptomatic and can be
recognized after routine blood screening. Alternatively, it can
manifest with mild neuromuscular irritability, calcification of the
basal ganglia, extrapyramidal disorders, cataracts, alopecia,
abnormal dentition, coarse brittle hair, mental retardation or
personality disorders (1, 2).
Biochemically, hypoparathyroidism is characterized by low
serum calcium concentrations and increased serum phosphate
levels in the presence of normal renal function. Serum concen-
trations of immunoreactive PTH are low or undetectable, except
in the setting of pseudo-hypoparathyroidism. 1,25(OH)2D serum
levels as well as nephrogenous cyclic AMP excretion are low,
whereas renal tubular reabsorption of phosphate is elevated (1).
Autoimmune PolyEndocrinopathy-Candidiasis-Ectodermal Dys -
t r o p h y (APECED), also known as autoimmune polyglandular
syndrome type I (OMIM 240300) is an autosomal recessive
disorder affecting many tissues, mainly endocrine glands (3, 4).
Hypoparathyroidism is one of the earliest and commonest
manifestations of the syndrome (3). APECED is caused by mu-
tations in a single gene on chromosome 21q22.3, named AIRE
(for autoimmune regulator), which encode a protein with the
characteristics of a transcription factor (3, 4).
In this report, we outline the long-term follow-up of a girl affect-
ed by APECED, in whom hypoparathyroidism represented the
first recognized manifestation.
Patient report
The patient was the third daughter of unrelated Italian parents
from a small town of the Liguria region. She was born in April
1978 after an uncomplicated pregnancy and delivery. At birth,
height was 49 cm and weight was 3150 g. Perinatal period was
normal.
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Table I - Hypoparathyroidism: clinical forms (2).
Agenesis or dysgenesis of the parathyroid glands
X-linked autosomal recessive hypoparathyroidism
DiGeorge syndrome
Hypoparathyroidism, sensorineural deafness and 
renal dysplasia syndrome
Hypoparathyroidism-retardation dysmorphism syndrome
Kenny-Caffey syndrome
Mitochondrial neuromyopathies
Kearns-Sayre syndrome
Pearson syndrome
Long-chain hydroxyacyl-CoA dehydrogenase deficiency
Destruction of the parathyroid glands
Postsurgical hypoparathyroidism
Hypoparathyroidism after radioactive iodine thyroid ablation
External radiation
I filtrative disorders
Hemochromatosis
Wilson’s disease
Granulomatous diseases
Metastases
Autoimmune polyendocrinopathy candidiasis-ectodermal dystrophy
syndrome
Impaired PTH secretion
Primary
PTH gene mutations - autosomal recessive /autosomal dominant
Activating mutations of the Ca2+-sensing receptor
Secondary
Maternal hyperparathyroidism
Hypomagnesemia
Target organ resistance
Primary
Pseudohypoparathyroidism (1A, pseudo, 1B, 1C, 2)
Secondary
Hypomagnesemia
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At the age 3 years, after some episodes interpreted as syn-
cope, the girl was referred to our Department for generalized
seizures. At admission, she presented with hypocalcemia, in-
creased levels of phosphate and PTH deficiency (Table II).
Family and personal history were uninformative, with the ex-
ception of mild oral candidiasis in the first year of life, com-
pletely recovered with regular antimycotic treatment. Height
and weight were normal for age and sex (Table II) and for her
mid-parental height [160 cm (-0.4 SDS)] (5). No other specific
clinical signs were found.
After correction of hypocalcemia by intravenous calcium infu-
sion, treatment with 1,25(OH)2D3 (0.25 mg thrice/day) and oral
calcium (500 mg twice/day) was successfully started. Therapy
was monitorized and adjusted to maintain adequate serum cal-
cium levels. The girl was well until the age 10 years, 8/12 when
she was admitted for hypovolemic shock. She presented with
dark skin and biochemical evaluation demonstrated sudden
adrenal crisis (Table II). Addison’s disease was diagnosed and
the patient started treatment with hydrocortisone (10-15
m g / m2/daily) and 9a-fludrocortisone (0.1 mg/daily). APECED
syndrome was suspected and auto-antibodies against adrenal
gland, ovary, skin, gastric parietal cells were found to be posi-
tive (C. Betterle, Padua).
Pubertal development started around the age 12 years, but it
arrested at the stage B2 (5); at this age pituitary gonadal-axis
evaluation showed hypergonadotropic hypogonadism and
sonography demonstrated small ovarian glands (Table II). Fe-
male secondary sexual characteristics was then induced by ad-
ministration of estro-progestin treatment.
In the following years, the patient developed severe nail can-
didiasis and recurrent periods of malabsorption, requiring to in-
crease 1,25(OH)2D3 (3-4 mg daily) and calcium (3-4 g daily)
doses to maintain low-normal calcium values; she also devel-
oped vitiligo and tooth enamel dystrophy, requiring teeth recon-
struction. When the patient was 22 year old, she had a short
period (3 months) of isolated hypertransaminasemia (2-3 times
the upper normal value), spontaneously recovered. Positive
antiglutamic acid decarboxylase (GAD) and anti-insulin (AIA)
antibodies was detected at the age 24 years [94.5 U/ml (n.v. <
0.9) and 16.1% (n.v. < 6.2)], but parameters of glucose home-
ostasis remained in the normal range (Table II). AIRE g e n e
analysis demonstrated, in a homozygous state, a missense
mutation in exon 2 (W78R).
Clinical and biochemical data as well as therapies at last fol-
low-up are summarized in Table II.
Discussion
In this paper, we report on long-term follow-up of a female pa-
tient affected by APECED. Despite severe expression of the
disease, the patient attained a final height adequate for her
mid-parental and normal bone mineral density in young adult-
hood, suggesting that an accurate multi-hormonal substitutive
treatment may permit good somatic and sexual development.
Hypoparathyroidism represented an isolated endocrine finding
for several years. Oral candidiasis was recorded in the first
months of life but, because it had been easily treated, this fea-
ture was not adequately taken into consideration. Severe can-
didiasis developed only at adolescence. So, the girl was con-
sidered affected by primary “isolated” hypoparathyroidism until
she was acutely admitted for an adrenal crisis. 
In fact, hypoparathyroidism in APECED appears early in child-
hood, usually between the age 5-10 years (6), while the other
main clinical components of the syndrome may did not develop
up to adolescence and some manifestations may not evolve
until the fifth decade of life or also later (4, 6). Thus, an exten-
sive history and accurate clinical and endocrinological surveil-
138 Clinical Cases in Mineral and Bone Metabolism 2004; 1(2): 137-141
S.Bertelloni et al.
Table II - Clinical data at diagnosis and during follow-up.
Parameter Patient Note
At first admission
Age, years 3, 4/12 –
Height, cm 93.5 -0.81 SDS*
Weight 13.2 -12%**
Calcium, mg/dL 4.5 n.v. 8.5-10.5
Phosphate, mg/dL 6.7 n.v. 2.5-5.0
Alkaline phospatase, UI/L 457 n.v. 380-640
PTH, pmol/L° undetectable n.v. 40-70
At adrenal crisis
Age, years 10, 8/12 –
Height, cm 137.0 -0.60 SDS*
Weight 24.7 -21.6 %**
Calcium, mg/dL 8.0 n.v. 8.5-10.5
Phosphate, mg/dL 5.6 n.v. 2.5-5.0
Sodium, mEq/L 125.0 n.v. 136-142
Potassium, mEq/L 6.1 n.v. 3.5-5.5
Cortisol, ng/mL 0.8 n.v. 60-300
ACTH, pg/mL >1250 n.v. 9-52
At diagnosis of hypogonadism
Age, years 11, 11/12 –
Height, cm 143.5 -0.76 SDS*
Weight 39.7 13.4%**
Calcium, mg/dL 8.0 n.v. 8.5-10.5
Phosphate, mg/dL 5.6 n.v. 2.5-5.0
Sodium, mEq/L 139.0 n.v. 136-142
Potassium, mEq/L 4.14 n.v. 3.5-5.5
17b-estradiol, pg/mL 12.7 29-270^
LH, UI/L 46.0 1.5-20^
FSH, UI/L 79.5 1.5-10^
Mean ovarian volume, mL 1.2 -2.0 SDS
At last follow-up
Age, years 26 –
Height, cm 161.5 -0.11 SDS*
Weight 66.5 18.7%**
Calcium, mg/dL 8.8 n.v. 8.5-10.5
Phosphate, mg/dL 4.2 n.v. 2.5-5.0
Sodium, mEq/L 140.0 n.v. 136-142
Potassium, mEq/L 4.28 n.v. 3.5-5.5
Fasting glucose, mg/dL 79.0 n.v. 65-110
Glucose peak°°, mg/dL 133.0 n.v. < 140
HbA1c, % 4.6 n.v. 3.4-5.8
Fasting insulin, mU/mL 8.5 n.v. 4.0-25
Lumbar BMD, g/cm2 1.142 -0.69***
1,25(OH)2D3, mg/day 0.75 –
Calcium, g/day 1.5 –
Hydrocortisone, mg/day 15 –
9a-fludrocortisone mg/day 0.5 –
17b-estradiol (20 mg/day) +
norelgetromin (150 mg/day) 21 days/28 days^–^
* According to Tanner et al. (%); ** of ideal body weight for height; ° RIA for
M-M PTH (44-68 region of human PTH); *** according to Boot et al. (J Clin
Endocrinol Metab 1997;82:57-62); ^ n.v. for follicular phase; ^^ transdermal.
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lance should be guaranteed to each child presenting with “idio-
pathic” hypoparathyroidism. Today, molecular evaluation of
A I R E gene may permit an early diagnosis (3), when other
known causes of hypoparathyroidism (Table I) have been ruled
out (2). Indeed, molecular analysis of A I R E and other genes
associated with hypoparathyroidism requires expert profession-
als and adequate technology. Reference laboratories to per-
form the molecular analysis in patients selected by restrictive
clinical and biochemical criteria should be established for large
macroareas. In fact, APECED is a rare disease (incidence
~1:100.000/year) (3, 4), and the health organization for these
patients should forecast laboratory and clinical reference cen-
ters connected with clinicians working at peripheral level by an
effective network. As other recessive genetic disorders, an
higher incidence has been found in some populations, who are
characterized by a high degree of consanguinity. In Italy, the
syndrome is more prevalent in Sardinian population (1:14.400)
(8). High incidence of APECED is also reported in Iranian Jews
(1:600 to 1:9.000) (9) and Finns (1:25.000) (10). The female to
male ratio in APECED varies from 0.8:1 to 2.4:1 (6, 11).
APECED is due to mutation in A I R E gene (3). This gene consists
of 14 exons spanning approximately 13 kb of genomic DNA and
encodes for a 545 aminoacid protein. It is especially prominent in
the nucleus of thymic medullary epithelial and dendritic antigen
presenting cells (3), and not in the target organs of APECED dis-
ease process (3, 12). A IR E gene likely plays a role in the induc-
tion of self-tolerance, enhancing the expression of peripheral anti-
gens in the thymus and by acting as co-activator of nuclear re-
ceptors involved in the process of clonal deletion (3, 4, 14). 
AIRE is expressed in the medullary epithelium of the thymus
(3); there is a close relationship between the thymic and
parathyroid epithelia because they originate from the third pha-
ryngeal pouches (14). Lack of AIRE may affect the negative
selection of T-cell normally executed by the thymic medullary
epithelial cells and thymic dendritic cells. The defective apopto-
sis of self reactive T-cells would represent the pathogenesis of
the disease (3, 4, 15).
At least 49 mutations have been described in the AIRE gene
(3); the most frequent of them include a typical Finnish muta-
tion (R257X) (3), also described in some patients from North-
ern Italy (15), the Sardinian mutation (R139X) (8), and the Jew-
ish-Iranian mutation (Y85C) (3). Previously unreported muta-
tions have been described in 11 patients (from 8 families) origi-
nating from a restricted area of Southern Italy (15). The W78R
missense mutation was relatively common in this group of pa-
tients, suggesting a founder effect (16). The same W78R muta-
tion has been detected in our girl, even if the evaluation of her
pedigree did not show any evidence of relatives fromSalento
peninsula, as previously reported in the other Italian patients
sharing the same mutation (16).Indeed, the W78R mutation
has been also described in one patient of Czech origin (17),
suggesting that sporadic mutations can occur outside from
S lento area.
The W78R mutation replacing a non polar aminoacid with a po-
lar basic residue (16) likely determines a large derangement of
AIRE gene as indicated by the early onset of APECED and the
severe clinical expression of the disease in our girl as well as in
the other reported subjects (16).
The APECED phenotype is inherited as an autosomal reces-
sive fashions homozygous or compound heterozygous state
(3). Indeed, recent data suggest that some mutations may act
as dominant, leading to overt APECED syndrome also in het-
erozygous subjects (18, 19).
Cli ically, candidal infection of the skin and mucous mem-
branes is one of the more frequent feature of APECED, being
present in the large majority of reported patients (6, 11, 15, 16,
18, 19), with slight differences between Northern Europe and
Italy (Table III). It is likely due to T-cell defect, but these sub-
jects do not show other clinical evidence of T-cell immunodefi-
ciency (4). As in the present girl, muco-cutaneous candidiasis
may represent the first clinical manifestation (3, 6, 18), but its
importance for diagnosis may be underestimated until the ap-
p arance of endocrine manifestations. In fact, candidiasis is of-
ten mild, in contrast with the extensive severe lesions of other
forms of chronic muco-cutaneous candidiasis (4), and affects
the skin in only 10% of the patients (6). As underlined in pre-
sent report, candidiasis is usually followed by hypoparathy-
roidism just in early childhood (4, 6, 11), mainly in females (13)
in whom it becomes manifest between the age of 5 to 10 years
by generalized seizures associated with hypocalcemia and low
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Table III - Main characteristics of the APECED syndrome reported in literature and in the present girl.
North Europe Italian Present 
patients* **patients** girl
n 90 53
Male/female 45/45 18/35
Endocrine manifestations (%)
Hypoparathyroidism 81 194 +
Addison’s disease 79 173 +
Hypogonadism 31 1#40# +
Type I diabetes 12 112 –
Thyroid disease °14° 117 –
Nonendocrine autoimmune manifestations (%)
Mucocutaneous candidiasis 94 185 +
Enamel hypoplasia °77° °°100°° +
Alopecia 31 141 –
Intestinal dysfunction 22 134 +
Vitiligo 21 113 +
Pernicious anemia 16 113 –
Autoimmune hepatitis 16 121 –^^
* Data from ref. 14; ** data from ref. 11, 16, 19; ° data from ref. 6; °° data only from ref. 16, 19; # of post-pubertal patients; ^ transient hypertrasaminasemia.
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or undetectable PTH concentrations (1, 4). About 1/4 of pa-
tients, mainly males (13), do not develop hypoparathyroidism.
The males also showed al later age at onset of hypoparathy-
oridism (13). The reason for this different evolution of the syn-
drome remain to be elucidated (3, 4), but the evidence that
most of the patients without hypoparathyroidism are males
suggests that sex may have some inferences on APECED
phenotype (13). Autoantibodies against several antigens of
parathyroid gland have been described (Table IV), but their in-
volvement in the pathogenesis of impaired PTH secretion re-
main to be better elucidated (3, 14).
Addison’s disease is the second most frequent endocrine dis-
orders in APECED with similar prevalence in Northern Europe
and Italy (Table III) and usually appear before the age of 15
years (4, 6, 11). Adrenal autoantibodies are directed against
some P450 cytochromes antigens [P450c21 (21-hydroxylase),
P450c17 (17-a -hydroxylase), P450scc (side chain cleavage
enzyme)] (3). These antigens are in adrenal cortex, and the lat-
ter two are also in the gonads (3, 14) (Table IV), suggesting
their direct involvement in both Addison’s disease and gonadal
failure. The autoantibodies inhibit the steroidogenic enzyme ac-
tivitiesin vitro (14), even if a clear pathological role in vivo has
not yet been demonstrated (20).
Other endocrine deficiencies are less frequent in APECED
(Table III) and are associated with specific autoantibodies
(Table IV) (3, 6, 11, 14). In this patient, high levels of GAD anti-
bodies were found, but she did not develop up to now any bio-
chemical signs of impaired glucose homeostasis. 
Several ectodermal manifestations of APECED are present in
the present patient (Table III). The pathogenetic mechanisms re-
main to be elucidated (3), but they are usually associated with
autoantibodies directed against specific tissue antigens (Table
IV) (3, 11, 19). About 20% of patients with APECED have fat
malabsorption which is often associated with weight loss, growth
retardation and malabsorption of medications (21, 22). The latter
finding complicated the clinical follow-up of this girl, leading to
ome episodes of hypocalcemia likely related to an abnormal
absorption of 1,25(OH)2D3 and calcium. In addition, when mal-
absorption recovered, the patient had some episodes of hyper-
c lcemia due to the increased drug dosages. So, a more strict
control of electrolytes may be request during these periods.
Malabsorption has been considered to be a non endocrine
manifestation of APECED (22). However, some evidences indi-
cate that an autoimmune attack against the cells of the gas-
trointestinal-associated system may be responsible of this dys-
function by tryptophan hydroxylase antibodies (23).
In conclusion, APECED syndrome is a rare disease, that
should be suspected in all patients affected by chronic candidi-
asis and autoimmune disorders. Diagnosis still rely on the clini-
cal evidence of two of the three major features (hypoparathy-
oidism, primary adrenocortical failure, and chronic muco-cuta-
neous candidiasis) in a single patient; it should be confirmed by
the detection of specific autoantibodies and, possibly, by AIRE
gene analysis. One major manifestation is sufficient to diag-
nose APECED in siblings of patients (3, 6, 11). After diagnosis
all patients require close monitoring and long-term follow-up to
prevent illness and lifetreating associated with delayed diagno-
sis of additional autoimmune diseases (4).
Further works are needed to fully explain why parathyroid
glands are affected so often in the patients lacking the function-
al products of the AIRE gene (13).
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